Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of WCK 2349 in Hepatic Impairment
NCT02244827Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alalevonadifloxacin in bacterial infection and acute bacterial skin and skin structure infections (ABSSSI), sponsored by Wockhardt. Primary endpoints: Area Under the Curve at 48 hours, Maximum Plasma Concentration at 48 hours and 4 more. Started Sep 2014; status: completed.
02
Drugs
alalevonadifloxacin
03
Conditions
bacterial infectionacute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02244827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244827.